ArticleMolecular vision2015

Simultaneous application of bevacizumab and anti-CTGF antibody effectively suppresses proangiogenic and profibrotic factors in human RPE cells.

Abouzar Bagheri et al.PubMed ↗Full text ↗

No numbers read from the abstract.